Shareholders’ Equity (Tables)

12 Months Ended

Dec. 31, 2025

Shareholders’ Equity [Abstract]

Schedule of Share Option Plan

A summary of the status of options under the Company’s share option plans as of December 31, 2025 and changes during the relevant period ended on that date is presented below:

	For the year ended December 31, 2025
	Number of options			Weighted average exercise price		Aggregate intrinsic value		Weighted average remaining contractual life (years)
Outstanding at beginning of year		14,449,650		$	4.62	$	2,964		6.92
Granted		2,714,633		$	3.08
Exercised		(176,496	)	$	1.54	$	603
Forfeited		(240,836	)	$	3.81
Outstanding at end of period		16,746,951		$	4.41	$	22,630		6.46
Exercisable options		12,333,008		$	4.79	$	14,907		5.71

Schedule of RSUs Under the Plan

A summary of the status of RSUs under the Plan as of December 31, 2025 and changes during the relevant period ended on that date is presented below:

	Number of RSUs			Weighted-average grant date fair value per share
Nonvested at beginning of year		857,899		$	4.24
Granted		775,706		$	2.89
Vested		(861,192	)	$	3.97
Forfeited		(24,907	)	$	4.58
Nonvested at end of year		747,506		$	3.16

Schedule of Total Equity-Based Compensation Expense

The total equity-based compensation expense related to all of the Company’s equity-based awards recognized for the years ended December 31, 2023, 2024 and 2025, was comprised as follows:

	Year ended December 31,
	2023		2024		2025
Research and development	$	5,073	$	6,454	$	6,464
Marketing expenses		474		753		859
General and administrative		2,379		2,709		3,294
Total share-based compensation expense	$	7,926	$	9,916	$	10,617